TY - JOUR
T1 - Preparation, characterization,and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model
AU - Ali, Hazem
AU - Kalashnikova, Irina
AU - White, Mark Andrew
AU - Sherman, Michael
AU - Rytting, Erik
N1 - Funding Information:
The authors are grateful to Dr. Joseph Reibenspies (Texas A&M University, College Station, TX) for providing the FIT2D software for X-ray diffraction analysis and to Sanaalarab Al Enazy for her assistance with the graphical abstract. E.R. is supported by a research career development award (K12HD052023: Building Interdisciplinary Research Careers in Women's Health Program, BIRCWH) from the National Institute of Allergy and Infectious Diseases (NIAID), the NICHD, and the Office of the Director (OD), National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, NICHD, OD, or the NIH.
PY - 2013
Y1 - 2013
N2 - The purpose of this study was to prepare dexamethasone-loaded polymeric nanoparticles and evaluate their potential for transport across human placenta. Statistical modeling and factorial design was applied to investigate the influence of process parameters on the following nanoparticle characteristics: particle size, polydispersity index, zeta potential, and drug encapsulation efficiency. Dexamethasone and nanoparticle transport was subsequently investigated using the BeWo b30 cell line, an in vitro model of human placental trophoblast cells, which represent the rate-limiting barrier for maternal-fetal transfer. Encapsulation efficiency and drug transport were determined using a validated high performance liquid chromatography method. Nanoparticle morphology and drug encapsulation were further characterized by cryo-transmission electron microscopy and X-ray diffraction, respectively. Nanoparticles prepared from poly(lactic-co-glycolic acid) were spherical, with particle sizes ranging from 140 to 298 nm, and encapsulation efficiency ranging from 52 to 89%. Nanoencapsulation enhanced the apparent permeability of dexamethasone from the maternal compartment to the fetal compartment more than 10-fold in this model. Particle size was shown to be inversely correlated with drug and nanoparticle permeability, as confirmed with fluorescently labeled nanoparticles. These results highlight the feasibility of designing nanoparticles capable of delivering medication to the fetus, in particular, potential dexamethasone therapy for the prenatal treatment of congenital adrenal hyperplasia.
AB - The purpose of this study was to prepare dexamethasone-loaded polymeric nanoparticles and evaluate their potential for transport across human placenta. Statistical modeling and factorial design was applied to investigate the influence of process parameters on the following nanoparticle characteristics: particle size, polydispersity index, zeta potential, and drug encapsulation efficiency. Dexamethasone and nanoparticle transport was subsequently investigated using the BeWo b30 cell line, an in vitro model of human placental trophoblast cells, which represent the rate-limiting barrier for maternal-fetal transfer. Encapsulation efficiency and drug transport were determined using a validated high performance liquid chromatography method. Nanoparticle morphology and drug encapsulation were further characterized by cryo-transmission electron microscopy and X-ray diffraction, respectively. Nanoparticles prepared from poly(lactic-co-glycolic acid) were spherical, with particle sizes ranging from 140 to 298 nm, and encapsulation efficiency ranging from 52 to 89%. Nanoencapsulation enhanced the apparent permeability of dexamethasone from the maternal compartment to the fetal compartment more than 10-fold in this model. Particle size was shown to be inversely correlated with drug and nanoparticle permeability, as confirmed with fluorescently labeled nanoparticles. These results highlight the feasibility of designing nanoparticles capable of delivering medication to the fetus, in particular, potential dexamethasone therapy for the prenatal treatment of congenital adrenal hyperplasia.
KW - BeWo cells
KW - Congenital adrenal hyperplasia
KW - Dexamethasone
KW - Nanoparticles
KW - Placenta
KW - Pregnancy
UR - http://www.scopus.com/inward/record.url?scp=84884163096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884163096&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2013.07.010
DO - 10.1016/j.ijpharm.2013.07.010
M3 - Article
C2 - 23850397
AN - SCOPUS:84884163096
SN - 0378-5173
VL - 454
SP - 149
EP - 157
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 1
ER -